Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.50 |
| ▸ | P4HA1 | P13674 | 3/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20396062 | 0.97 | ALDH1A1 (0.50) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL4886683 | 0.80 | ALDH1A1 (0.58) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL20396058 | 0.77 | NAPRT (0.40) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL3718941 | 0.77 | KCNJ1 (0.38) | ALDH1A1HSD17B10KDM4EALOX15P4HA1 | |
| SCHEMBL3705899 | 0.76 | ALDH1A1 (0.54) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL185448 | 0.76 | ALDH1A1 (0.54) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL186175 | 0.74 | GABRP (0.58) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL63857 | 0.74 | NAPRT (0.58) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL16749632 | 0.74 | ALDH1A1 (0.52) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 | |
| SCHEMBL5660197 | 0.74 | P4HA1 (0.56) | ALDH1A1HSD17B10KDM4EALOX15HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12480049-B2 | Compound and liquid crystal composition | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20230250338-A1 | COMPOUND AND LIQUID CRYSTAL COMPOSITION | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-08-10 | — | — | US | disclosed |
| CN-116554889-A | Compound and liquid crystal composition | 香港科技大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-113149981-B | Protein degradation targeting chimera for degrading androgen receptor | 苏州德亘生物医药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-113149981-A | Protein degradation targeting chimera for degrading androgen receptor | 苏州德亘生物医药有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-110177783-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-102757420-B | Heterotactic aryl carboxylic acid compound, preparation method thereof, medicine composition comprising compound and application of compound | SHANGHAI INST MATERIA MEDICA | 2015-02-04 | — | — | CN | disclosed |
| CN-102757420-A | Heterotactic aryl carboxylic acid compound, preparation method thereof, medicine composition comprising compound and application of compound | SHANGHAI INST MATERIA MEDICA | 2012-10-31 | — | — | CN | disclosed |
| US-20080119651-A1 | one pot reaction without isolating intermediates; reacting oxoalkonate with urea, trimethyl orthoformate in methanol or ethanol to yield a 2-acyl-3-ureidoacrylate, reacting intermediate with 2-hydroxypyrimidine-5-carboxylate in presence of alkali alkoxide, convering it to halo compds. with PO2Cl or SOCl2 | LONZA AG (CH) | 2008-05-22 | — | — | US | disclosed |
| EP-1809609-B1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| EP-1809609-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048297-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119651-A1 | one pot reaction without isolating intermediates; reacting oxoalkonate with urea, trimethyl orthoformate in methanol or ethanol to yield a 2-acyl-3-ureidoacrylate, reacting intermediate with 2-hydroxypyrimidine-5-carboxylate in presence of alkali alkoxide, convering it to halo compds. with PO2Cl or SOCl2 | HPD, DCTD, POLD1 | ALDH1A1 582/4885HSD17B10 1682/4885KDM4E 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.